Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

LNPs are solid or semi-solid particles at room temperature. They are composed of a lipid core stabilized by surfactants or other agents. This lipid core provides a hydrophobic environment ideal for ...

Using cryogenic mass spectrometry, scientists from the University of Nottingham’s School of Pharmacy and their collaborators elsewhere developed an approach for depth profiling frozen lipid ...

Encapsulating an active substance in a liposome or lipid nanoparticle can minimize cytotoxicity and increase blood circulation by bypassing the immune system. Several techniques can improve a drug's ...

Messenger ribonucleic acid (mRNA)-based therapeutics and the potential of mRNA as a treatment for various conditions has been researched for decades. A key challenge remains finding a delivery system ...

The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

A new study shows that lipid nanoparticles restructure their membrane significantly after being absorbed into a cell and ending up in an acidic environment. (Nanowerk News) Vaccines and other ...

Researchers have developed a new lipid nanoparticle design that directs mRNA to the pancreas by exploiting the organ’s own filtration barrier, a strategy that sidesteps the liver-trapping problem that ...